CenExel, a leading network of clinical research sites, proudly congratulates and announces its role in supporting Vertex Pharmaceuticals’ clinical studies that led to the FDA approval of JOURNAVX™ ...

UnitedHealth reported fourth-quarter adjusted EPS of $6.81, up from $6.16 a year ago, beating the consensus of $6.72.

Journave, the first non-addictive opioid-like pain medication, was developed based on Yale research from the ’90s.

As shares of Boston-based Vertex shot higher on the news of its non-opioid pill, Journavx, we took a look at investment in ...

Federal officials have approved a new type of pain pill designed to eliminate the risks of addiction and overdose associated with opioid medications like Vicodin and OxyContin. The U.S.

The Phase IIa results continue a surge of momentum in a treatment space that last week saw the approval of Vertex’s Journavx ...

Vertex Pharmaceuticals ( VRTX 2.53%) has long been known as the company to turn to for life-saving cystic fibrosis (CF) drugs ...

The FDA has approved a new non-opioid prescription medication, Journavx for adults with moderate to severe acute pain.

A new painkiller that is said to be free of addiction risks may be transformative for treatment of acute pain, according to local medical professionals. "I think it could be a potentially ...

The opioid epidemic continues to affect hundreds of thousands of people, but there may be hope for the future with a new, non ...